Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment

Publication date: Available online 24 June 2020Source: Molecular Genetics and MetabolismAuthor(s): Beth L. Thurberg, George A. Diaz, Robin H. Lachmann, Thomas Schiano, Melissa P. Wasserstein, Allena J. Ji, Atef Zaher, M. Judith Peterschmitt
Source: Molecular Genetics and Metabolism - Category: Genetics & Stem Cells Source Type: research
More News: Genetics